<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34617955</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>14</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>14</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">2374-2445</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>7</Volume>
            <Issue>12</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Dec</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>JAMA oncology</Title>
          <ISOAbbreviation>JAMA Oncol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor-Positive, ERBB2-Negative Advanced Breast Cancer: A Randomized Clinical Trial.</ArticleTitle>
        <Pagination>
          <StartPage>1791</StartPage>
          <EndPage>1799</EndPage>
          <MedlinePgn>1791-1799</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaoncol.2021.4301</ELocationID>
        <Abstract>
          <AbstractText Label="IMPORTANCE">The cyclin-dependent kinase 4 and 6 inhibitor palbociclib in combination with letrozole has become a standard first-line treatment for patients with endocrine-sensitive, hormone receptor-positive, ERBB2-negative advanced breast cancer. Meanwhile, the antiestrogen fulvestrant was shown to be superior to anastrozole in the absence of cyclin-dependent kinase 4 and 6 inhibition for this patient population.</AbstractText>
          <AbstractText Label="OBJECTIVE">To assess whether fulvestrant is superior to letrozole when combined with palbociclib in the first-line scenario.</AbstractText>
          <AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">In this international, randomized, open-label, phase 2 clinical study conducted from July 30, 2015, to January 8, 2018, patients with hormone receptor-positive, ERBB2-negative advanced breast cancer with no prior therapy in the metastatic setting and endocrine-sensitive criteria were recruited from 47 centers in 7 countries. Data were analyzed from February 11 to May 15, 2020.</AbstractText>
          <AbstractText Label="INTERVENTIONS">Patients were randomly assigned (1:1 ratio) to receive palbociclib with either fulvestrant or letrozole. Stratification factors were type of disease presentation (de novo vs recurrent) and the presence of visceral involvement (yes vs no).</AbstractText>
          <AbstractText Label="MAIN OUTCOMES AND MEASURES">The primary end point was investigator-assessed progression-free survival determined by Response Evaluation Criteria in Solid Tumors, version 1.1.</AbstractText>
          <AbstractText Label="RESULTS">A total of 486 women (median age, 63 years [range, 25-90 years]; 3 Asian women [0.6%]; 4 Black women [0.8%]; 461 White women [94.9%]; 18 women of unknown race [3.7%]) were randomized (243 to fulvestrant-palbociclib and 243 to letrozole-palbociclib). Median investigator-assessed progression-free survival was 27.9 months (95% CI, 24.2-33.1 months) in the fulvestrant-palbociclib group vs 32.8 months (95% CI, 25.8-35.9 months) in the letrozole-palbociclib group (hazard ratio, 1.13; 95% CI, 0.89-1.45; P = .32). This result was consistent across the stratification factors. No significant differences were observed in objective response rate (46.5% vs 50.2%) and 3-year overall survival rate (79.4% vs 77.1%) for fulvestrant-palbociclib and letrozole-palbociclib, respectively. Grade 3-4 adverse events were comparable among treatment groups, and no new safety signals were identified. No treatment-related deaths were reported.</AbstractText>
          <AbstractText Label="CONCLUSIONS AND RELEVANCE">Although fulvestrant-palbociclib demonstrated significant antitumor activity, this randomized clinical trial failed to identify an improvement in progression-free survival with this regimen over letrozole-palbociclib in patients with endocrine-sensitive, hormone receptor-positive, ERBB2-negative advanced breast cancer.</AbstractText>
          <AbstractText Label="TRIAL REGISTRATION">ClinicalTrials.gov Identifier: NCT02491983.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Llombart-Cussac</LastName>
            <ForeName>Antonio</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Hospital Arnau de Vilanova, Universidad Católica, Valencia, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Medica Scientia Innovation Research, Barcelona, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Medica Scientia Innovation Research, Ridgewood, New Jersey.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pérez-García</LastName>
            <ForeName>José Manuel</ForeName>
            <Initials>JM</Initials>
            <AffiliationInfo>
              <Affiliation>Medica Scientia Innovation Research, Barcelona, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Medica Scientia Innovation Research, Ridgewood, New Jersey.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>International Breast Cancer Center Quiron Group, Barcelona.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bellet</LastName>
            <ForeName>Meritxell</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Vall d'Hebrón Institute of Oncology, Medical Oncology Department, Vall d'Hebrón University Hospital, Barcelona, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dalenc</LastName>
            <ForeName>Florence</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Medical Oncology Department, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse-Oncopole, Centre de recherches en cancérologie, Inserm, Toulouse, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gil-Gil</LastName>
            <ForeName>Miguel</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Medical Oncology Department, Institut Català d'Oncología, Insitut d'Investigació Biomèdica Bellvitge, Barcelona, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ruíz-Borrego</LastName>
            <ForeName>Manuel</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Hospital Universitario Virgen del Rocío, Sevilla, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gavilá</LastName>
            <ForeName>Joaquín</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Medical Oncology Department, Fundación Instituto Valenciano de Oncología, Valencia, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sampayo-Cordero</LastName>
            <ForeName>Miguel</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Medica Scientia Innovation Research, Barcelona, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Medica Scientia Innovation Research, Ridgewood, New Jersey.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Aguirre</LastName>
            <ForeName>Elena</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Medica Scientia Innovation Research, Barcelona, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Medica Scientia Innovation Research, Ridgewood, New Jersey.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Schmid</LastName>
            <ForeName>Peter</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, and Barts Hospital, NHS Trust, London, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Marmé</LastName>
            <ForeName>Frederik</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>University Hospital Heidelberg, Medical Faculty Mannheim Heidelberg University, Heidelberg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Di Cosimo</LastName>
            <ForeName>Serena</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Medica Scientia Innovation Research, Barcelona, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Medica Scientia Innovation Research, Ridgewood, New Jersey.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Biomarkers Unit, Department of Applied Research and Technological Development, Fondazione Istituto Di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milano, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gligorov</LastName>
            <ForeName>Joseph</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Institut Universitaire de Cancérologie Assistance Publique-Hôpitaux de Paris, Sorbonne Université, Paris, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Schneeweiss</LastName>
            <ForeName>Andreas</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>National Center for Tumor Diseases, Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Albanell</LastName>
            <ForeName>Joan</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Research Program, Hospital del Mar Research Institute, Barcelona, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Medical Oncology Department, Hospital del Mar, Barcelona, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Universitat Pompeu Fabra, Barcelona, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Centro de Investigación Biomédica en Red de Oncología, Madrid, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zamora</LastName>
            <ForeName>Pilar</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Medical Oncology Department, Hospital Universitario La Paz, Madrid, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wheatley</LastName>
            <ForeName>Duncan</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Royal Cornwall Hospitals NHS Trust, Truro, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Martínez-de Dueñas</LastName>
            <ForeName>Eduardo</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Medical Oncology Department, Hospital Provincial Castellón, Castelló De La Plana, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Amillano</LastName>
            <ForeName>Kepa</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Medical Oncology Department, Hospital Universitari Sant Joan de Reus, Reus, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Malfettone</LastName>
            <ForeName>Andrea</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Medica Scientia Innovation Research, Barcelona, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Medica Scientia Innovation Research, Ridgewood, New Jersey.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cortés</LastName>
            <ForeName>Javier</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Medica Scientia Innovation Research, Barcelona, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Medica Scientia Innovation Research, Ridgewood, New Jersey.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>International Breast Cancer Center Quiron Group, Barcelona.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Vall d'Hebrón Institute of Oncology, Barcelona, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <CollectiveName>PARSIFAL Steering Committee and Trial Investigators</CollectiveName>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <DataBankList CompleteYN="Y">
          <DataBank>
            <DataBankName>ClinicalTrials.gov</DataBankName>
            <AccessionNumberList>
              <AccessionNumber>NCT02491983</AccessionNumber>
            </AccessionNumberList>
          </DataBank>
        </DataBankList>
        <PublicationTypeList>
          <PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>JAMA Oncol</MedlineTA>
        <NlmUniqueID>101652861</NlmUniqueID>
        <ISSNLinking>2374-2437</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010879">Piperazines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011725">Pyridines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>22X328QOC4</RegistryNumber>
          <NameOfSubstance UI="D000077267">Fulvestrant</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>7LKK855W8I</RegistryNumber>
          <NameOfSubstance UI="D000077289">Letrozole</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.1</RegistryNumber>
          <NameOfSubstance UI="C508053">ERBB2 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.1</RegistryNumber>
          <NameOfSubstance UI="D018719">Receptor, ErbB-2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>G9ZF61LE7G</RegistryNumber>
          <NameOfSubstance UI="C500026">palbociclib</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="ErratumIn">
          <RefSource>JAMA Oncol. 2021 Nov 1;7(11):1729</RefSource>
          <PMID Version="1">34792545</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001943" MajorTopicYN="Y">Breast Neoplasms</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077267" MajorTopicYN="N">Fulvestrant</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077289" MajorTopicYN="N">Letrozole</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011725" MajorTopicYN="N">Pyridines</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018719" MajorTopicYN="N">Receptor, ErbB-2</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Llombart-Cussac reported playing a leadership role at Eisai, Celgene, Lilly, Pfizer, Roche, Novartis, and Merck Sharp &amp; Dohme Corp; intellectual property for Medica Scientia Innovation Research and Initia-Research; serving in a consulting role for Lilly, Roche, Pfizer, Novartis, Pierre-Fabre, Genomic Health, and GlaxoSmithKline; being part of the speaker bureau for Lilly, AstraZeneca, and Merck Sharp &amp; Dohme Corp; receiving research funding from Roche, Foundation Medicine, Pierre-Fabre, and Agendia; and receiving travel compensation from Roche, Lilly, Novartis, Pfizer, and AstraZeneca during the conduct of the study. Dr Pérez-García reported having a consulting role for Roche, Lilly, and Daichii-Sankyo; receiving travel compensation from Roche; and being a part-time employee of Medica Scientia Innovation Research during the conduct of the study. Dr Bellet reported receiving honoraria from Pfizer, Novartis, and Lilly; travel compensation from Pfizer and Roche; having a consulting role for Pfizer, Novartis, and Lilly; and being part of the speaker bureau for Pfizer, Novartis, and Lilly during the conduct of the study. Dr Gil-Gil reported receiving honoraria from Pfizer, Novartis, and Eisai; receiving travel compensation from Khern, Daiichi, Pfizer, and Roche; and serving as a consultant to Daiichi, Agendia, and Genomic Health during the conduct of the study. Dr Ruíz-Borrego reported serving as a consultant to Novartis, Pfizer, and Merck Sharp &amp; Dohme Corp; and serving on the speaker bureau for Pfizer, Novartis, Roche, Lilly, and AstraZeneca during the conduct of the study. Dr Gavilá reported receiving honoraria from Pfizer, Novartis, Lilly, and Roche; receiving travel compensation from Roche; serving as a consultant to Pfizer, Novartis, Lilly, and Merck Sharp &amp; Dohme Corp; and being on the speaker bureau for Novartis and Pfizer during the conduct of the study. Mr Sampayo-Cordero reported receiving honoraria from Medica Scientia Innovation Research, Syntax for Science, and Nestlé; research funding from Medica Scientia Innovation Research, Syntax for Science, and Roche; travel compensation from Medica Scientia Innovation Research, Syntax for Science, and Roche; serving as a consultant to Medica Scientia Innovation Research, Syntax for Science, and Nestlé; being on the speaker bureau for Medica Scientia Innovation Research, Syntax for Science, and Roche; and being a part-time employee of Medica Scientia Innovation Research during the conduct of the study. Dr Aguirre reported having a consulting role with Merck Sharp &amp; Dohme Corp, AstraZeneca, Pfizer, and Roche during the conduct of the study. Dr Schmid reported receiving honoraria from Pfizer, AstraZeneca, Novartis, Roche, Merck, and Boehringer Ingelheim; having a consulting role for Pfizer, AstraZeneca, Novartis, Roche, Merck, Boehringer Ingelheim, Bayer, Eisai, Celgene, and Puma; and having institutional grants from Roche, Genentech, Oncogenex, and Novartis during the conduct of the study. Dr Marmé reported receiving honoraria from Roche/Genentech, Novartis, Pfizer, AstraZeneca, Tesaro, Clovis Oncology, Eisai, Celgene, Genomic Health, PharmaMar, Amgen, CureVac, Merck Sharp &amp; Dohme Corp Oncology, Janssen-Cilag, and ImmunoMedics (to the institution); institutional research funding from Roche/Genentech, Novartis, AstraZeneca, Eisai, Tesaro, Clovis, Merck Sharp &amp; Dohme Corp Oncology, and Vaccibody; travel compensation from Roche, Pfizer, Novartis, PharmaMar, and AstraZeneca; and serving as a consultant to Tesaro, Pfizer, Novartis, GenomicHealth, CureVac, Amgen, Celgene, Eisai, Janssen-Cilag, AstraZeneca (to institution), Roche (to institution), Vaccibody (to institution), and ImmunoMedics (to institution) during the conduct of the study. Dr Di Cosimo reported receiving fees for medical education from Novartis and Pierre-Fabre; being a recipient of the IG20774 of Fondazione Associazione Italiana Ricerca contro il Cancro; and being a part-time employee of Medica Scientia Innovation Research during the conduct of the study. Dr Gligorov reported serving as a consultant to Daiichi, Eisai, Genomic Health, Immunomedics, Ipsen, Macrogenics, Merck Sharp &amp; Dohme Corp, Mylan, Novartis, Onxeo, Pfizer, and Roche; being on the speaker bureau for Eisai, Genomic Health, Ipsen, Merck Sharp &amp; Dohme Corp, Mylan, Novartis, Pfizer, and Roche; receiving research funding from Eisai, Genomic Health, and Roche; and receiving travel compensation from Eisai, Genomic Health, Merck Sharp &amp; Dohme Corp, Mylan, Novartis, Pfizer, and Roche during the conduct of the study. Dr Schneeweiss reported receiving honoraria from Roche, Celgene, Pfizer, AstraZeneca, Novartis, Merck Sharp &amp; Dohme Corp, Tesaro, and Lilly; research funding from Celgene, Roche, AbbVie, and Molecular Partner; travel compensation from Celgene and Roche; and providing expert testimony for Roche and AstraZeneca during the conduct of the study. Dr Albanell reported receiving grants from Medica Scientia Innovation Research; serving as a consultant to Pfizer, Roche, Amgen, Merck Sharp &amp; Dohme Corp, and Lilly; being part of the speaker bureau for Roche and Pfizer; receiving research funding from Roche and Seattle Genetics, travel compensation from Roche, Pfizer, Amgen, Merck Sharp &amp; Dohme Corp, and Lilly, and royalties from Biocartis; having a patent for EGFRmut licensed to Biocartis; and having a patent for InBiomotion during the conduct of the study. Dr Zamora reported receiving research funding from Roche and travel compensation from Roche and Pfizer during the course of the study. Dr Wheatley reported receiving honoraria from Pfizer, Roche, Daiichii Sankyo, Novartis, and Lilly; receiving travel compensation from Roche; serving as a consultant to Pfizer, Roche, and Lilly; being on the speaker bureau for Lilly, Pfizer, and Novartis; and receiving personal fees from AstraZeneca for work on the advisory board during the course of the study. Dr Martínez-de Dueñas reported receiving honoraria from Pfizer; travel compensation from Roche; and serving as a consultant to Pfizer and Novartis during the course of the study. Dr Malfettone reported being a full-time employee of Medica Scientia Innovation Research. Dr Cortés reported serving as a consultant to Roche, Celgene, Cellestia, AstraZeneca, Biothera Pharmaceutical, Merus, Seattle Genetics, Daiichi Sankyo, Erytech, Athenex, Polyphor, Lilly, Servier, Merck Sharp &amp; Dohme, GlaxoSmithKline, Leuko, Bioasis, and Clovis Oncology; providing intellectual property to Medica Scientia Innovation Research; receiving honoraria from Roche, Novartis, Celgene, Eisai, Pfizer, Samsung Bioepis, Lilly, Merck Sharp &amp; Dohme, and Daiichi Sankyo; and receiving institutional research funding from Roche, Ariad Pharmaceuticals, AstraZeneca, Baxalta GMBH/Servier Affaires, Bayer Healthcare, Eisai, Hoffmann-La Roche, Guardant Health, Merck Sharp &amp; Dohme, Pfizer, Piqur Therapeutics, Puma C, and Queen Mary University of London during the course of the study. No other disclosures were reported.</CoiStatement>
      <InvestigatorList>
        <Investigator ValidYN="Y">
          <LastName>Antón</LastName>
          <ForeName>Antonio</ForeName>
          <Initials>A</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Moiseyenko</LastName>
          <ForeName>Vladimir</ForeName>
          <Initials>V</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Cottu</LastName>
          <ForeName>Paul</ForeName>
          <Initials>P</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Viñas</LastName>
          <ForeName>Gemma</ForeName>
          <Initials>G</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Petit</LastName>
          <ForeName>Thierry</ForeName>
          <Initials>T</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Tesarova</LastName>
          <ForeName>Petra</ForeName>
          <Initials>P</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Vladimirov</LastName>
          <ForeName>Vladimir</ForeName>
          <Initials>V</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Cueva Bañuelos</LastName>
          <ForeName>Juan</ForeName>
          <Initials>J</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Colleoni</LastName>
          <ForeName>Marco</ForeName>
          <Initials>M</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Bertelli</LastName>
          <ForeName>Gianfilippo</ForeName>
          <Initials>G</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Martínez</LastName>
          <ForeName>Purificación</ForeName>
          <Initials>P</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Andres</LastName>
          <ForeName>Raquel</ForeName>
          <Initials>R</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Barannikova</LastName>
          <ForeName>Tatiana</ForeName>
          <Initials>T</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Servitja</LastName>
          <ForeName>Sonia</ForeName>
          <Initials>S</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Medioni</LastName>
          <ForeName>Jacques</ForeName>
          <Initials>J</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Cinieri</LastName>
          <ForeName>Saverio</ForeName>
          <Initials>S</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Bayo</LastName>
          <ForeName>Juan</ForeName>
          <Initials>J</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>González</LastName>
          <ForeName>Santiago</ForeName>
          <Initials>S</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Melichar</LastName>
          <ForeName>Bohuslav</ForeName>
          <Initials>B</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Caranyana</LastName>
          <ForeName>Vicente</ForeName>
          <Initials>V</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Atzori</LastName>
          <ForeName>Francesco</ForeName>
          <Initials>F</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Beresford</LastName>
          <ForeName>Mark</ForeName>
          <Initials>M</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Chan</LastName>
          <ForeName>Steven</ForeName>
          <Initials>S</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Luque-Cabal</LastName>
          <ForeName>Maria</ForeName>
          <Initials>M</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>de la Haba</LastName>
          <ForeName>Juan</ForeName>
          <Initials>J</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Bischoff</LastName>
          <ForeName>Joachim</ForeName>
          <Initials>J</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Mukhametsina</LastName>
          <ForeName>Guzel</ForeName>
          <Initials>G</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Cazzaniga</LastName>
          <ForeName>Maria</ForeName>
          <Initials>M</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Generali</LastName>
          <ForeName>Daniele</ForeName>
          <Initials>D</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Wardley</LastName>
          <ForeName>Andrew</ForeName>
          <Initials>A</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Cortesi</LastName>
          <ForeName>Laura</ForeName>
          <Initials>L</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Cavanna</LastName>
          <ForeName>Luigi</ForeName>
          <Initials>L</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Airoldi</LastName>
          <ForeName>Mario</ForeName>
          <Initials>M</Initials>
        </Investigator>
      </InvestigatorList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pmc-release">
          <Year>2022</Year>
          <Month>10</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>7</Day>
          <Hour>12</Hour>
          <Minute>22</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34617955</ArticleId>
        <ArticleId IdType="pmc">PMC8498933</ArticleId>
        <ArticleId IdType="doi">10.1001/jamaoncol.2021.4301</ArticleId>
        <ArticleId IdType="pii">2784608</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Cardoso F, Costa A, Senkus E, et al. . 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). Ann Oncol. 2017;28(1):16-33. doi:10.1093/annonc/mdw544
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdw544</ArticleId>
            <ArticleId IdType="pmc">PMC5378224</ArticleId>
            <ArticleId IdType="pubmed">28177437</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hortobagyi GN, Stemmer SM, Burris HA, et al. . Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol. 2018;29(7):1541-1547. doi:10.1093/annonc/mdy155
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdy155</ArticleId>
            <ArticleId IdType="pubmed">29718092</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rugo HS, Finn RS, Diéras V, et al. . Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. Breast Cancer Res Treat. 2019;174(3):719-729. doi:10.1007/s10549-018-05125-4
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10549-018-05125-4</ArticleId>
            <ArticleId IdType="pmc">PMC6438948</ArticleId>
            <ArticleId IdType="pubmed">30632023</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johnston S, Martin M, Di Leo A, et al. . MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. NPJ Breast Cancer. 2019;5:5. doi:10.1038/s41523-018-0097-z
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41523-018-0097-z</ArticleId>
            <ArticleId IdType="pmc">PMC6336880</ArticleId>
            <ArticleId IdType="pubmed">30675515</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Di Leo A, Jerusalem G, Petruzelka L, et al. . Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol. 2010;28(30):4594-4600. doi:10.1200/JCO.2010.28.8415
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2010.28.8415</ArticleId>
            <ArticleId IdType="pubmed">20855825</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Slamon DJ, Neven P, Chia S, et al. . Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol. 2018;36(24):2465-2472. doi:10.1200/JCO.2018.78.9909
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2018.78.9909</ArticleId>
            <ArticleId IdType="pubmed">29860922</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sledge GW Jr, Toi M, Neven P, et al. . MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017;35(25):2875-2884. doi:10.1200/JCO.2017.73.7585
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2017.73.7585</ArticleId>
            <ArticleId IdType="pubmed">28580882</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cristofanilli M, Turner NC, Bondarenko I, et al. . Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17(4):425-439. doi:10.1016/S1470-2045(15)00613-0
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(15)00613-0</ArticleId>
            <ArticleId IdType="pubmed">26947331</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Slamon DJ, Neven P, Chia S, et al. . Overall survival with ribociclib plus fulvestrant in advanced breast cancer. N Engl J Med. 2020;382(6):514-524. doi:10.1056/NEJMoa1911149
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1911149</ArticleId>
            <ArticleId IdType="pubmed">31826360</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sledge GW Jr, Toi M, Neven P, et al. . The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial. JAMA Oncol. 2020;6(1):116-124. doi:10.1001/jamaoncol.2019.4782
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaoncol.2019.4782</ArticleId>
            <ArticleId IdType="pmc">PMC6777264</ArticleId>
            <ArticleId IdType="pubmed">31563959</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Robertson JFR, Bondarenko IM, Trishkina E, et al. . Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet. 2016;388(10063):2997-3005. doi:10.1016/S0140-6736(16)32389-3
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(16)32389-3</ArticleId>
            <ArticleId IdType="pubmed">27908454</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Finn RS, Martin M, Rugo HS, et al. . Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375(20):1925-1936. doi:10.1056/NEJMoa1607303
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1607303</ArticleId>
            <ArticleId IdType="pubmed">27959613</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Finn RS, Crown JP, Lang I, et al. . The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16(1):25-35. doi:10.1016/S1470-2045(14)71159-3
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(14)71159-3</ArticleId>
            <ArticleId IdType="pubmed">25524798</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Food and Drug Administration . Non-inferiority clinical trials to establish effectiveness guidance for industry. Accessed March 30, 2020. https://www.fda.gov/media/78504/download</Citation>
        </Reference>
        <Reference>
          <Citation>Tripathy D, Im SA, Colleoni M, et al. . Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018;19(7):904-915. doi:10.1016/S1470-2045(18)30292-4
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(18)30292-4</ArticleId>
            <ArticleId IdType="pubmed">29804902</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Albanell J, Martinez MTM, Ramos M, et al. . LBA19 GEICAM/2014-12 (FLIPPER) study: First analysis from a randomized phase II trial of fulvestrant (F)/palbociclib (P) versus (vs) F/placebo (PL) as first-line therapy in postmenopausal women with HR (hormone receptor)+/HER2– endocrine sensitive advanced breast cancer (ABC). Ann Oncol. 2020;31(S4):S1151. doi:10.1016/j.annonc.2020.08.2247
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.annonc.2020.08.2247</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Turner NC, Slamon DJ, Ro J, et al. . Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med. 2018;379(20):1926-1936. doi:10.1056/NEJMoa1810527
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1810527</ArticleId>
            <ArticleId IdType="pubmed">30345905</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>US Food and Drug Administration. FDA warns about rare but severe lung inflammation with Ibrance, Kisqali, and Verzenio for breast cancer. December 20, 2019. Accessed December 11, 2020. https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-rare-severe-lung-inflammation-ibrance-kisqali-and-verzenio-breast-cancer</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
